Capital Research Global Investors Boosts Stake in Vertex Pharmaceuticals

Institutional investor increases holding in biotech firm by 2.8% in Q3

Mar. 10, 2026 at 11:49am

Got story updates? Submit your updates here. ›

Capital Research Global Investors, a major institutional investor, has increased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.8% during the third quarter, according to a recent SEC filing. The fund now owns 16,553,281 shares of the pharmaceutical company's stock, representing a 6.52% ownership position.

Why it matters

Vertex Pharmaceuticals is a leading biotech firm focused on developing treatments for serious diseases like cystic fibrosis. The increase in ownership by a prominent institutional investor like Capital Research Global Investors signals confidence in the company's growth prospects and pipeline.

The details

According to the SEC filing, Capital Research Global Investors acquired an additional 444,990 shares of Vertex Pharmaceuticals during the third quarter. This brings the firm's total holding in the company to 16,553,281 shares, valued at approximately $6.48 billion as of the most recent quarter. The increased stake makes Capital Research Global Investors the 17th largest holder of Vertex Pharmaceuticals stock.

Capital Research Global Investors filed the 13F report disclosing the increased stake on March 10, 2026.
The additional 444,990 shares were acquired during the third quarter of 2025.

The players